GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » 12-1 Month Momentum %

PHAR (Pharming Group) 12-1 Month Momentum % : -10.94% (As of Apr. 23, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Pharming Group 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-04-23), Pharming Group's 12-1 Month Momentum % is -10.94%.

The industry rank for Pharming Group's 12-1 Month Momentum % or its related term are showing as below:

PHAR's 12-1 Month Momentum % is ranked better than
60.36% of 1443 companies
in the Biotechnology industry
Industry Median: -18.64 vs PHAR: -10.94

Competitive Comparison of Pharming Group's 12-1 Month Momentum %

For the Biotechnology subindustry, Pharming Group's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Pharming Group's 12-1 Month Momentum % falls into.


;
;

Pharming Group  (NAS:PHAR) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group  (NAS:PHAR) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Pharming Group 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Pharming Group's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines